Birdwatch Note
2024-08-15 05:59:53 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
“Chimpanzee adenoviral (ChAd) vectors have been developed as vaccine candidates for multiple infectious diseases and prostate cancer. ChAd vectors are safe and induce antigen-specific cellular and humoral immunity in all age groups.” Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718829/
Written by 67C6AA96F849E4E3A995C7BBA3BBA906DE16F7EFB14EA0950EAD84EBE3E0AC64
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1823902876344967402
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1823962799837733063
- noteId - 1823962799837733063
- participantId -
- noteAuthorParticipantId - 67C6AA96F849E4E3A995C7BBA3BBA906DE16F7EFB14EA0950EAD84EBE3E0AC64
- createdAtMillis - 1723701593727
- tweetId - 1823902876344967402
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- “Chimpanzee adenoviral (ChAd) vectors have been developed as vaccine candidates for multiple infectious diseases and prostate cancer. ChAd vectors are safe and induce antigen-specific cellular and humoral immunity in all age groups.” Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718829/
Note Ratings
| rated at | rated by | |
| 2024-08-20 06:33:46 -0500 | Rating Details | |
| 2024-08-16 01:05:37 -0500 | Rating Details | |
| 2024-08-15 19:18:06 -0500 | Rating Details | |
| 2024-08-15 13:51:14 -0500 | Rating Details | |
| 2024-08-15 13:45:38 -0500 | Rating Details | |
| 2024-08-15 13:06:34 -0500 | Rating Details | |
| 2024-08-15 09:36:17 -0500 | Rating Details | |
| 2024-08-15 08:45:11 -0500 | Rating Details | |
| 2024-08-15 08:10:06 -0500 | Rating Details | |
| 2024-08-15 07:48:54 -0500 | Rating Details | |
| 2024-08-15 07:14:54 -0500 | Rating Details | |
| 2024-08-15 03:44:07 -0500 | Rating Details | |
| 2024-08-15 03:43:13 -0500 | Rating Details | |
| 2024-08-15 03:37:19 -0500 | Rating Details | |
| 2024-08-15 03:33:10 -0500 | Rating Details | |
| 2024-08-15 03:30:33 -0500 | Rating Details | |
| 2024-08-15 02:42:55 -0500 | Rating Details | |
| 2024-08-15 01:55:16 -0500 | Rating Details | |
| 2024-08-15 01:54:55 -0500 | Rating Details | |
| 2024-08-15 01:51:23 -0500 | Rating Details | |
| 2024-08-15 01:37:17 -0500 | Rating Details | |
| 2024-08-15 01:14:52 -0500 | Rating Details | |
| 2024-08-15 12:41:58 -0500 | Rating Details | |
| 2024-08-15 08:47:58 -0500 | Rating Details | |
| 2024-08-15 08:39:44 -0500 | Rating Details | |
| 2024-08-15 07:57:32 -0500 | Rating Details | |
| 2024-08-15 07:43:26 -0500 | Rating Details | |
| 2024-08-15 07:19:50 -0500 | Rating Details | |
| 2024-08-15 06:53:22 -0500 | Rating Details | |
| 2024-08-15 06:09:20 -0500 | Rating Details | |
| 2024-08-15 02:49:41 -0500 | Rating Details | |
| 2024-08-15 01:42:48 -0500 | Rating Details | |
| 2024-08-15 01:02:28 -0500 | Rating Details |